gfp p53 (Addgene inc)
Structured Review
Gfp P53, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 54 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gfp+p53/GFP-p53+(Plasmid+%2312091)/pm41729074-131-7-15
Average 93 stars, based on 54 article reviews
Images
Related Articles
Transfection:Article Title: Complementary omics strategies to dissect p53 signaling networks under nutrient stress Article Snippet: .. Cells transfected with Over Expression:Article Title: Complementary omics strategies to dissect p53 signaling networks under nutrient stress Article Snippet: .. Cells transfected with Fluorescence:Article Title: Complementary omics strategies to dissect p53 signaling networks under nutrient stress Article Snippet: .. Cells transfected with Imaging:Article Title: Complementary omics strategies to dissect p53 signaling networks under nutrient stress Article Snippet: .. Cells transfected with Mutagenesis:Article Title: A novel peptide explicitly induces prostate cancer cell death by destabilizing AR and inhibiting AR-mediated transcription. Article Snippet: Current treatment strategies for prostate cancer primarily focuses on regulating androgen receptor (AR) activity, either through androgen deprivation or the use of anti-androgen therapies.. While these approaches are initially effective, many patients eventually develop resistance, resulting in the emergence of castration-resistant prostate cancer (CRPC).. This transition not only complicates disease management but also leads to persistent side effects, underscoring the urgent need for alternative therapeutic strategies that directly target AR or disrupt its interactions with co-regulatory proteins. Construct:Article Title: A novel peptide explicitly induces prostate cancer cell death by destabilizing AR and inhibiting AR-mediated transcription. Article Snippet: Current treatment strategies for prostate cancer primarily focuses on regulating androgen receptor (AR) activity, either through androgen deprivation or the use of anti-androgen therapies.. While these approaches are initially effective, many patients eventually develop resistance, resulting in the emergence of castration-resistant prostate cancer (CRPC).. This transition not only complicates disease management but also leads to persistent side effects, underscoring the urgent need for alternative therapeutic strategies that directly target AR or disrupt its interactions with co-regulatory proteins. Generated:Article Title: A novel peptide explicitly induces prostate cancer cell death by destabilizing AR and inhibiting AR-mediated transcription. Article Snippet: Current treatment strategies for prostate cancer primarily focuses on regulating androgen receptor (AR) activity, either through androgen deprivation or the use of anti-androgen therapies.. While these approaches are initially effective, many patients eventually develop resistance, resulting in the emergence of castration-resistant prostate cancer (CRPC).. This transition not only complicates disease management but also leads to persistent side effects, underscoring the urgent need for alternative therapeutic strategies that directly target AR or disrupt its interactions with co-regulatory proteins. Plasmid Preparation:Article Title: A novel peptide explicitly induces prostate cancer cell death by destabilizing AR and inhibiting AR-mediated transcription. Article Snippet: Current treatment strategies for prostate cancer primarily focuses on regulating androgen receptor (AR) activity, either through androgen deprivation or the use of anti-androgen therapies.. While these approaches are initially effective, many patients eventually develop resistance, resulting in the emergence of castration-resistant prostate cancer (CRPC).. This transition not only complicates disease management but also leads to persistent side effects, underscoring the urgent need for alternative therapeutic strategies that directly target AR or disrupt its interactions with co-regulatory proteins. Hemagglutination Assay:Article Title: Ubiquitin ligase Nedd4 regulates the abundance and toxicity of mutant huntingtin Article Snippet: .. HA-WT-Ub (#17608), HA-K0-Ub (#17603), scramble shRNA (#1864), shRNA:Article Title: Ubiquitin ligase Nedd4 regulates the abundance and toxicity of mutant huntingtin Article Snippet: .. HA-WT-Ub (#17608), HA-K0-Ub (#17603), scramble shRNA (#1864), Article Title: TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma Article Snippet: .. Article Title: TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. Article Snippet: .. Sequencing:Article Title: TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma Article Snippet: .. Article Title: TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. Article Snippet: .. other:Article Title: Ubiquitin ligase Nedd4 regulates the abundance and toxicity of mutant huntingtin. Article Snippet: The following reagents were purchased as indicated: DMEM (11995065, Thermo Fisher), L-Glutamine (25030081, Thermo Fisher), Penicillin-Streptomycin (15140122, Thermo Fisher), Neurobasal media (21103049, Thermo Fisher), B-27 Supplement (17504044, Thermo Fisher), N-ethylmaleimde (23030, Thermo Fisher), PMSF (36978, Thermo Fisher), ZeptoMetrix RETROtek HIV-1 p24 Antigen ELISA (22-156-700, Fisher), FBS (100-106, Gemini Bio), CHX (14126, Cayman Chemical), bafilomycin A1 (11038, Cayman Chemical), bortezomib (#2204, Cell Signaling Technology), Ponseau S (P7170, Sigma), rapamycin (R8781, Sigma), cOmplete mini EDTA-free protease inhibitor cocktail (11836170001, Sigma), Protein A-Sepharose (P3391, Sigma), Protein G-Agarose (P4691, Sigma), Vectashield mounting medium with DAPI (H-1200, Vector Laboratories), Lenti-X concentrator (631232, TaKaRa), RNase-free DNase (79254, Qiagen), and Ub aldehyde (U-201-050, R&D Systems). |
